• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

Novartis

lymphatic vessels
Posted inNew Drugs, Rare/Orphan Diseases, Regulatory

Vijoice: First Targeted Treatment for PIK3CA-Related Overgrowth Spectrum (PROS)

by Tanya von Reuss April 23, 2022September 8, 2022

Novartis and its alpelisib will help with very rare diseases with malformations and excessive tissue growth.

Posted inNew Drugs, Regulatory

Vabysmo: New Drug for Wet Age-Related Macular Degeneration and Diabetic Macular Edema

by Tanya von Reuss February 1, 2022September 8, 2022

Faricimab by Roche is a strong competitor to Eylea.

Posted inNew Drugs, Regulatory

Susvimo: Pioneering Implant for Treating Wet Age-Related Macular Degeneration

by Julia Mardi January 20, 2022September 8, 2022

Roche offered a convenient replacement for the traditional Lucentis.

Posted inClinical Trials, In the Pipeline, Neuroscience

Treating Parkinson’s Disease: Betting on Alpha-Synuclein

by Mark Gubar and Julia Mardi January 14, 2022April 11, 2024

The pharmaceutical industry continues to fight hard against the devastating neurodegenerative disease.

T cell.
Posted inAutoimmune Diseases, Clinical Trials, Neuroscience

Even Severe Multiple Sclerosis Can Be Cured

by Nik Resovski and Julia Mardi January 11, 2022September 8, 2022

Atara Biotherapeutics and its awesome T-cell therapy against Epstein–Barr virus can really cure progressive forms of multiple sclerosis.

Posted inClinical Trials, COVID-19, Infections

Ensovibep: Drug for All Variants of Coronavirus Including Omicron

by Mark Gubar January 10, 2022September 8, 2022

Molecular Partners and Novartis believe in the success of DARPins.

Posted inNeuroscience, Pharma & Biotech, Rare/Orphan Diseases

Biogen to Develop Updated Version of Spinraza

by Julia Mardi January 5, 2022September 8, 2022

Nusinersen for the treatment of spinal muscular atrophy will get a follow-up.

Posts pagination

Newer posts 1 2 3 4 Older posts
BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×